Prime Medicine Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, everyone. My name is Maury Raycroft, and one of the biotech analysts at Jefferies. I am happy to introduce and welcome Allan Reine, the CEO of Prime Medicine. Thanks for joining us today, Allan.
Maury, thanks for having us.
Appreciate being here. We are going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to the company.
Yeah, one minute is always tough to explain Prime Medicine. I just used up about four seconds of that. Prime Medicine, I think about it as really a next-generation gene editing technology. You can really think about it as the most versatile way to edit the genome. So we can do any kind of edit, any other gene editing kind of technology can do, but then so many more different variations and things that other gene editing technologies really can't do. So it is extremely versatile, but it is also very safe in the way we edit. So, you are doing single-stranded breaks. It is a more precise way to edit. It is a company that is now, we are going towards our first approval next year, for an ex vivo program, and something called chronic granulomatous disease.
We've just announced first patient dose in our Wilson program, and we've got our Alpha-1 IND now active. We're going to get to some pretty important clinical data inflection points next year as well. Maybe just to round out the one minute, I would just say, there's a lot of opportunity other than just things we're focusing on today. As we de-risk that, we think there's a lot to leverage down the road as we think about additional indications, both big and medium-sized.
Got it. Yeah, that was great. You got a lot into the minute there. Maybe starting with Wilson disease, you dosed your first patient in your global phase I/II in October. Can you walk us through how enrollment's going for the study, how many sites are open, which countries, and how quickly you're finding the patients?
Yeah, so the first site, or the first country that we said the trial was sort of good to go in was New Zealand. That was the first geography, and then we announced the IND subsequent to that. Now we're up and running in the U.S. So we've got the site in New Zealand. In the U.S., there's going to be obviously multiple sites, so there's a number that are being I know we have a number of site initiation visits soon. In addition to some of the sites that are already up and going, there's going to be a lot of additional sites, and then Europe as well. This is a global study. We're going to have multiple sites. In terms of an update on enrollment, I mean, we announced the first patient dosed in early October.
We're not going to give updates beyond that. The next you'll hear about the program is likely when we announce the clinical data. What I can say is there's a lot of excitement from both the patients and physicians. From at least what I can see, I think this is a trial that's going to enroll well. This is an area where we believe there's significant unmet need and high degree of motivation or a very motivated patient population that's looking for new treatments like this to really change the course of their disease.
Got it. You have a lead-in observational study. How is that helping with recruitment? You already have a lot of patients lined up in the queue for dose escalation.
Yeah, so we started what we call an observational study late last year. That is a study where we can go and really genotype these patients and observe. So through that, we have identified a significant number of H1069Q mutated patients, which are the Wilson disease patients that are going to be eligible for this trial. As we get the sites up and running where we have identified these patients, those will definitely be patients that can either come into the initial trial, because remember, this is a dose escalation, call it at least a few cohorts. So, just thinking about like a three patient per cohort, in and around there, you are looking at just nine patients, call it. You can always expand from there.
But as we think about expanding this beyond the initial cohorts, we think there are a lot of patients out there to go after, both in the U.S. and ex-U.S.
For the initial nine patients, you basically, do you have line of sight to those patients then, or?
It's not like we're going to screen as we go from patient to patient, but I'd say there's a lot of patients that have been identified or sites that have identified. You still go through the process for this study to actually go through that screening and get that patient into the study. I wouldn't say we've got nine patients identified today that we know we're going to enroll, but I would say there's a lot more than that likely that investigators have. I don't see enrollment to the study being an issue.
Got it. Okay. Is there a standard 30-day safety monitoring for a dose-limiting toxicity window between patients, or is there a longer safety observation period?
No, there's not a longer safety period than that. It's a little nuanced, but you can have different staggering in different geographies. The U.S. is pretty standardized now, but other geographies can be shorter. I'd say that's sort of the minimum amount of time between cohorts. But if you're just talking about the U.S., there's kind of shorter potential staggers as you look ex-U.S. as well.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
